All Supplement articles
View all stories of the same content type.
-
SupplementIdentification and management of colitis in primary care—practical tips and considerations
This supplement has been commissioned and funded by Ferring Pharmaceuticals and developed in partnership with Guidelines in Practice.
View prescribing and adverse event reporting information for Cortiment® (budesonide) and Pentasa® (mesalazine)
UK-GAS-2100137 December 2021 -
Supplement
Overcoming challenges in managing obesity in primary care
Information intended for UK healthcare professionals only. This supplement has been funded through an arm’s-length sponsorship by Novo Nordisk Limited. Guidelines in Practice approached Novo Nordisk Limited to fund the production of the supplement.
Date of preparation: December 2021 -
Supplement
NICE atrial fibrillation: diagnosis and management guideline (NG196) update—treatment considerations for direct-acting oral anticoagulants (DOACs)
Information intended for UK healthcare professionals only. This round-table discussion supplement has been commissioned and funded by Bayer plc and developed in partnership with Guidelines in Practice.
View Xarelto®▼ (rivaroxaban) adverse event reporting and prescribing information
PP-XAR-GB-2369
Date of preparation: November 2021 -
Supplement
The unrecognised epidemic of vitamin D deficiency in Black, Asian and Minority Ethnic (BAME) groups: a consensus document
Information intended for UK healthcare professionals only. This supplement has been commissioned and funded by STADA incorporating Thornton & Ross, who provided the content.
TR-088d Date of preparation: August 2021 -
Supplement
Guideline for the managed introduction of biosimilar bolus insulin in individuals with type 2 diabetes
This working party guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Sanofi Ltd
-
Supplement
Real-world usage study and survey of oral bowel cleansing for colonoscopy in Dudley, UK
This supplement has been commissioned by Norgine Pharmaceuticals Limited and contains promotional information. Information for healthcare professionals only.
Click here for PLENVU® (macrogol 3350, sodium ascorbate, ascorbic acid, sodium sulfate anhydrous, potassium chloride, sodium chloride) Prescribing and Adverse Event Reporting.
Click here for MOVIPREP® ((macrogol 3350, sodium sulfate anhydrous, ascorbic acid, sodium ascorbate, sodium chloride, and potassium chloride) Prescribing and Adverse Event Reporting.
Click here for KLEAN-PREP (macrogol 3350, anhydrous sodium sulfate, sodium bicarbonate, sodium chloride, potassium chloride) Prescribing and Adverse Event Reporting.
UK-GE-PLV-2000027
Date of preparation: February 2021 -
Supplement
Showcasing local best practice in diabetes
This Guidelines in Practice supplement aims to showcase local best practice in the diagnosis and management of diabetes. The supplement includes articles from three local initiatives that have developed their own guidance or demonstrated improvements in different areas of diabetes care: Dr David Unwin shares ...
-
Supplement
Diabetes quality improvement at Barking and Dagenham: closing the inequalities gap
Dr Anju Gupta and Richard Clements explain how improvements in the quality of diabetes care were achieved, and variation reduced, in a socioeconomically deprived London borough
-
Supplement
Local, evidence-based guidance: optimising treatment of type 2 diabetes in Birmingham
Professor Wasim Hanif, Dr Nashat Qamar, and Hanadi Alkhder discuss the need for local guidance on non-insulin antidiabetic agents for adults with type 2 diabetes, and the important role played by the multidisciplinary team
-
Supplement
Successful dietary management of type 2 diabetes: experience from Norwood Surgery in Southport
Dr David Unwin shares details of how a GP practice in Liverpool has supported patients to achieve drug-free type 2 diabetes remission through dietary management
-
Supplement
Identification and management of patients with malnutrition
This supplement has been commissioned and funded by Alliance Pharmaceuticals Ltd and developed in partnership with Guidelines in Practice.
-
Supplement
Guideline for the managed introduction of biosimilar basal insulin
This working party guideline was developed by a multidisciplinary expert panel: Down S et al with the support of a grant from Mylan.
